An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.

Stopped Trial has been cancelled due to availability of new therapeutic options for patient population

Conditions

• Renal Impairment
• End-stage Renal Disease

Interventions

• DRUG: Simeprevir (SMV) 150 mg
• DRUG: Daclatasvir (DCV) 60 mg

Sponsor

Janssen R&D Ireland